Quicker access to innovative healthcare for UK patients. The Accelerated Access Review: final report now published

CLLSA is pleased to share that the Accelerated Access Review final report has now been published; it has been long awaited.

‘This review was commissioned by the government in November 2014. The final report makes new recommendations that set out how patients could get quicker access to innovative new diagnostic tools, treatments, and medical technologies.'

About the review

SNIP:

The review, developed in partnership with the Wellcome Trust, recommends the creation of a new accelerated access partnership to speed up and simplify the process for getting the most promising new treatments and diagnostics safely from pre-clinical development to patients. Patients expect the NHS to provide life-changing innovations as soon as they become available – but evidence has shown that the UK sometimes lags behind other countries.

The review says that accessing innovation in the NHS has become increasingly challenging. This creates frustration for clinicians and patients who often have to wait for life-saving treatments, and for innovators who must navigate multiple processes before their products can be used.

Through the new partnership, innovators would be able to access joined-up help for clinical development, regulation, and assessment of cost effectiveness. It is recommended that the partnership includes NHS England, NHS Improvement, the National Institute for Health and Care Excellence (NICE) and the Medicines and Healthcare Products Regulatory Agency (MHRA).

Patient access to drugs could be brought forward by up to 4 years if a scientific opinion from the early access to medicines scheme is used (saving 12 to 18 months) and there is no delay during the technology appraisal (which can take up to 2 years) or during the process for NHS commissioning and adoption (which can take 2 years or more).

 https://www.gov.uk/government/news/getting-patients-quicker-access-to-innovative-healthcare 

'The AAR has been led by an independent chair, Sir Hugh Taylor, supported by Sir John Bell as Chair of the External Advisory Group. There has been extensive engagement with industry, the NHS, patients, academia and clinicians during its development.'

 

Let's hope that the government now sees this as an opportunity for growth and a truly collaborative approach across all the stakeholder groups develops from this, There is no more money in the pot and innovative solutions and strategies are required to ensure UK patients gain access to latest transformational treatments and technologies as they come available..

 

“This has to be good news for CLL patients if it means that our members can get quicker access to the new drugs that are coming on stream. We shall of course be keeping a close eye on how this develops and we shall keep members informed." David Innes CLLSA Chair

 

Accelerated Access Review: Final Report

Sets out recommendations to speed up access to innovative healthcare and technologies, to improve efficiency and outcomes for NHS patients.  

https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/562101/AAR_final_report_A.pdf

SNIP: “Executive Summary

The Accelerated Access Review was asked to make recommendations to Government on how to accelerate access for NHS patients to innovative medicines, medical technologies, diagnostics and digital products, making our country the bes t place in the world to design, develop and deploy these innovations.

The Review’s independent chair, Sir Hugh Taylor, published an i nterim report in October 2015, setting out t he key themes emerging from the review team’s engagement with a wide range of stakeholders. Since then the r eview team has been carrying out further engagement and refining the recommendations.

This report sets out the final recommendations of the Accelerated Access Review. We believe that these recommendations will enable our country to improve patient outcomes, leverage the UK’s strong biosciences research and life sciences industrial base and enhance the international competitiveness of our life sciences industry. These recommendations will, of course, always need to be delivered within the budgetary envelope set by the Government for the NHS.

The recommendations are:

1. The NHS should develop an enhanced horizon scanning process and clarify its needs toinnovators.

2. A new transformative designation should be applied to those innovations with the potential for

3. Patients should be involved in horizon scanning and prioritisation, and this involvement should continue along the whole innovation pathway.

4. An Accelerated Access Pathway for strategically important, transformative products should align and coordinate regulatory, reimbursement, evaluation and diffusion processes to bri these transformative products to patients more quickly.

5. A new strategic commercial unit should be established in NHS England.

6. The accelerated access pathway should be suitable for medical technologies, diagnostics and digital products as well as medicines and emerging forms of treatment.

7. There should be a single set of clear national and local routes to get medical technologies,

diagnostics, pharmaceuticals and digital products to patients.

8. National routes to market should be streamlined and clarified.

9. Many products will benefit from regional and local routes to market, which should be enhanced to operate consistently across the NHS.

10. The route for digital products should build on the Paperless 2020 simplified app assessment process.

11. The digital infrastructure should enable the system to capture information on the use of innovations and associated outcomes.

12. The process of assessing emerging technologies should be evolved so that it is fit for the future.

13. A range of incentives should support the local uptake and spread of innovation, enabling collaboration and with greater capacity and capability for change.

14. AHSNs, tertiary academic teaching hospitals and clinical leaders across the NHS should drive and support the evaluation and diffusion of innovative products.

15. Improved accountability and transparency around uptake of innovation should be supported by NICE.

16. An Accelerated Access Partnership should align national bodies around accelerating innovation.

17. The Accelerated Access Partnership should be established immediately.

18. Implementation of the report’s recommendations should be led by the Accelerated Access Partnership and clinicians.”